English

Year-end report  January - December 2011

Report this content

Fourth quarter 2011

  • Net sales are unchanged and are reported at 116.0 MSEK (116.1). At comparable exchange rates sales increased by 3 percent
  • The operating result amounted to 9.8 MSEK (-435.9)1)
  • A 7.3 MSEK (15.0) additional purchase payment for the Biosystems business area divested in 2008 was received from Qiagen
  • The result after tax amounted to 17.2 MSEK (-424.8)1)
  • Earnings per share amounted to 0.22 SEK (-5.33)1)
  • Net cash at December 31, 2001 amounted to 198.4 MSEK (172.7)
  • During the quarter 648,456 own shares were purchased. At the balance sheet date December 31, 2011 Biotage owned a total of 3,266,956 own shares, acquired for 20,311 KSEK at an average share price of 6.22 SEK per share
  • The cash flow from operating activities amounted to 33.2 MSEK (12.1)

Full year 2011

  • Net sales are almost unchanged and are reported at 428.4 MSEK (428.9). At comparable exchange rates net sales increased by 8 percent
  • The operating result amounted to 25.1 MSEK (-418.8)1)
  • The result after tax amounted to 32.5 MSEK (-410.2)1)
  • Earnings per share amounted to 0.42 SEK (-4.91)1)
  • The dividends to shareholders are proposed to be raised to 0.40 SEK (0.25) per share
  • The cash flow from operating activities amounted to 94.8 MSEK (34.2)

1)    The comparative figure for 2010 includes an amortization of Group goodwill to the amount of 444.5 MSEK, which was charged to the operating result and corresponded to -5.55 SEK per share.


For further information, please contact:

Torben Jörgensen, President and CEO, phone: +46 707 49 05 84         
Erika Söderberg Johnson, CFO, phone: +46 730 50 80 56          


The information in this press release is of the kind that Biotage AB (publ) is required to make public according to the Financial Instruments Trading Act. The information was released for publication at 8.00am CET on February 9, 2012.

About Biotage
Biotage offers solutions, knowledge and experience in the areas of analytical chemistry and medicinal chemistry. The customers include the world’s largest pharmaceutical and biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has offices in the US, UK, China and Japan. Biotage has 270 employees and had sales of 428.1 MSEK in 2011. Biotage is listed on the NASDAQ OMX Nordic Stockholm stock exchange. Website: www.biotage.com

Tags:

Year-End Report Biotage

Documents & Links